The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …

Our objective was to update the EULAR recommendations for the management of systemic
lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic …

Disease modification has become a well-established concept in several therapeutic areas;
however, no widely accepted definition of disease modification exists for SLE. We reviewed …

Objective To evaluate the prevalence, duration and effect on damage accrual of the 'Lupus
Low Disease Activity State'(LLDAS) in a monocentric cohort of patients with systemic lupus …

Objective To investigate predictors of response, remission, low disease activity, damage,
and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were …

Objective To evaluate disease activity statuses'(DAS') impact on systemic lupus
erythematosus (SLE) outcomes. Materials and methods Four DAS were defined: remission …

Objectives There is an unmet need for accurate and user-friendly definitions of systemic
lupus erythematosus (SLE) disease activity and remission. We aimed to derive and validate …

Background Treat-to-target goals for patients with systemic lupus erythematosus (SLE) have
been validated to protect against organ damage and to improve quality of life. We aimed to …

Objectives Composite criteria/indices are presently used to diagnose and monitor patients
with systemic lupus erythematosus (SLE). Biomarkers for these purposes would be helpful in …

Objective To determine the independent impact of different definitions of remission and low
disease activity (LDA) on damage accrual. Methods Patients with≥ 2 annual assessments …